From Momenta:
"Necuparanib (formerly M402) is a novel, rationally
designed, oncology drug candidate under investigation in metastatic
pancreatic cancer. The use of heparins to treat venous thrombosis in
cancer patients has generated numerous reports of antitumor activity;
however, the dose of these products has been limited by their
anticoagulant activity. Necuparanib, which is derived from
unfractionated heparin, has been engineered to have significantly
reduced anticoagulant activity while preserving the relevant antitumor
properties of heparin. Necuparanib binds to multiple growth factors,
adhesion molecules, and chemokines to inhibit tumor angiogenesis,
progression, and metastasis."
JUST REMEMBER HEPARAN SURFACE IF THE COVER OF ESTROGEN RECEPTORS AND MANY OTHER RECEPTORS HUMMMM! CAN THIS PRODUCT WORK IN ER POSITIVE TUMOR?
" Twelve patients treated with necuparanib plus Abraxane and Gemzar
completed the first 28-day treatment cycle. They had at least one follow
up CT scan and were considered eligible for evaluating radiographic
response. Out of them, seven patients showed a RECIST partial response
and four patients reported stable disease.
Moreover, 11 out of
the 12 patients showed a more than 50% decrease in CA19.9 levels (a
predictive biomarker for long-term outcome and treatment response in
pancreatic cancer) from baseline. The remaining patient achieved a more
than 20% decrease from baseline. Overall, disease control was achieved
in 92% of these 12 patients."
No comments:
Post a Comment